3 hasil untuk "Stephan Stenglein"
Menampilkan 1–3 · 1,10 detik · RSS
-
Artikel Jurnal
Safety, tolerability, pharmacokinetics, and pharmacodynamics of zapnometinib: results from a phase I clinical study
IntroductionZapnometinib (ATR-002) is a selective MEK inhibitor designed to modulate the MAPK/ERK pathway, which plays a key role in viral infections and inflammatory diseases. Clinical characterization of its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) is essential to…
-
Artikel Jurnal
Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trialResearch in context
Summary: Background: Zapnometinib is an oral, non-ATP-competitive, small-molecule inhibitor of MEK1/MEK2 with immunomodulatory and antiviral properties. We aimed to investigate the safety and efficacy of zapnometinib in patients with COVID-19. Methods: In this randomised, double-blind…
-
Artikel Jurnal
Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients
IntroductionIn severe COVID-19, direct-acting antiviral drugs were not effective in hyperinflammatory stages and steroid treatment may weaken host immunity. The MEK inhibitor zapnometinib, as a host-targeting drug, has demonstrated promising efficacy against severe acute viral infections…